Drug Overview: Roxadustat

  • ID: 4462213
  • Drug Pipelines
  • 18 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Roxadustat (FibroGen/Astellas/AstraZeneca) is a hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitor in development for the treatment of anemia in chronic kidney disease. The drug is administered orally three times per week and mimics the body’s natural response to reduced oxygen levels by increasing levels of HIFs. These factors are involved in erythropoiesis. Roxadustat treats anemia primarily by reducing hepcidin levels, increasing iron transport and absorption proteins, and stimulating erythropoietin production.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
roxadustat: Anemia in chronic kidney disease

List of Figures
Figure 1: Roxadustat for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 3: Drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

List of Tables
Table 1: Roxadustat drug profile
Table 2: Roxadustat Phase III trials in anemia in chronic kidney disease
Table 3: Roxadustat Phase II and III data in anemia in chronic kidney disease
Table 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll